Drug maker Natco Pharma has reached a settlement with Onyx Therapeutics Inc. on a patent litigation related to generic versions of anti-cancer drug Kyprolis (10mg, 30mg and 60mg).
The parties have reached an agreement and the district court case has been dismissed. By virtue of the settlement, Natco and its U.S. marketing partner Breckenridge have been granted a licence permitting the launch of their generic, Carfilzomib, on a date held as confidential, in 2027 or sooner depending on certain occurrences.
The parties cannot make further comment as to the terms of the settlement agreement, a statement from Natco Pharma on Thursday said. Kyprolis, which is used to treat patients with relapsed or refractory multiple myeloma, had sales of $586 million for the year ended December 2018 in the U.S.
Marketing exclusivity
NATCO believes that its 10 mg ANDA is the sole first to file and could be eligible for 180-day marketing exclusivity for the 10 mg strength under certain circumstances, the release said. Shares of the Hyderabad-headquartered firm closed at ₹515.90 apiece, down 1.45%, on BSE.
